Literature DB >> 28378640

Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma.

Hamzeh Karimkhanloo1, Samira Mohammadi-Yeganeh2,3, Zeinab Ahsani1,4, Mahdi Paryan5.   

Abstract

Hepatocellular carcinoma is the major form of primary liver cancer, which is the second and sixth leading cause of cancer-related death in men and women, respectively. Extensive research indicates that Wnt/β-catenin signaling pathway, which plays a pivotal role in growth, development, and differentiation of hepatocellular carcinoma, is one of the major signaling pathways that is dysregulated in hepatocellular carcinoma. Cyclin D1 is a proto-oncogene and is one of the major regulators of Wnt signaling pathway, and its overexpression has been detected in various types of cancers including hepatocellular carcinoma. Using several validated bioinformatic databases, we predicted that the microRNAs are capable of targeting 3'-untranslated region of Cyclin D1 messenger RNA. According to the results, miR-20a was selected as the highest ranking microRNA targeting Cyclin D1 messenger RNA. Luciferase assay was recruited to confirm bioinformatic prediction results. Cyclin D1 expression was first assessed by quantitative real-time polymerase chain reaction in HepG2 cell line. Afterward, HepG2 cells were transduced by lentiviruses containing miR-20a. Then, the expression of miR-20a and Cyclin D1 was evaluated. The results of luciferase assay demonstrated targeting of 3'-untranslated region of Cyclin D1 messenger RNA by miR-20a. Furthermore, 238-fold decline in Cyclin D1 expression was observed after lentiviral induction of miR-20a in HepG2 cells. The results highlighted a considerable effect of miRNA-20a induction on the down-regulation of Cyclin D1 gene. Our results suggest that miR-20a can be used as a novel candidate for therapeutic purposes and a biomarker for hepatocellular carcinoma diagnosis.

Entities:  

Keywords:  Bioinformatics; Cyclin D1; hepatocellular carcinoma; microRNA

Mesh:

Substances:

Year:  2017        PMID: 28378640     DOI: 10.1177/1010428317698361

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  MiR-200a inhibits cell proliferation and EMT by down-regulating the ASPH expression levels and affecting ERK and PI3K/Akt pathways in human hepatoma cells.

Authors:  Wei-Feng Yao; Jun-Wei Liu; Dong-Sheng Huang
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

2.  Interplay of miRNAs and Canonical Wnt Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Xiaobo Nie; Yiran Liu; Wei-Dong Chen; Yan-Dong Wang
Journal:  Front Pharmacol       Date:  2018-06-21       Impact factor: 5.810

3.  miR-20a regulates sensitivity of colorectal cancer cells to NK cells by targeting MICA.

Authors:  Siwen Tang; Hongyu Fu; Qihua Xu; Ying Zhou
Journal:  Biosci Rep       Date:  2019-07-02       Impact factor: 3.840

Review 4.  Function and mechanisms of microRNA-20a in colorectal cancer.

Authors:  Zheng Xiao; Shi Chen; Shujun Feng; Yukun Li; Juan Zou; Hui Ling; Ying Zeng; Xi Zeng
Journal:  Exp Ther Med       Date:  2020-01-08       Impact factor: 2.447

5.  The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer.

Authors:  Martha L Slattery; Lila E Mullany; Lori C Sakoda; Roger K Wolff; John R Stevens; Wade S Samowitz; Jennifer S Herrick
Journal:  Mol Carcinog       Date:  2017-11-19       Impact factor: 4.784

6.  DNA methylation biomarkers for hepatocellular carcinoma.

Authors:  Guorun Fan; Yaqin Tu; Cai Chen; Haiying Sun; Chidan Wan; Xiong Cai
Journal:  Cancer Cell Int       Date:  2018-09-17       Impact factor: 5.722

7.  Downregulation of miR-193a-3p is involved in the pathogenesis of hepatocellular carcinoma by targeting CCND1.

Authors:  Shi-Shuo Wang; Zhi-Guang Huang; Hua-Yu Wu; Rong-Quan He; Li-Hua Yang; Zhen-Bo Feng; Yi-Wu Dang; Hui-Ping Lu; Ye-Ying Fang; Gang Chen
Journal:  PeerJ       Date:  2020-02-10       Impact factor: 2.984

8.  Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises).

Authors:  Sarah El-Nakeep
Journal:  World J Gastrointest Pathophysiol       Date:  2022-01-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.